European Pharmaceutical Review

SEPTEMBER 12, 2023

Over 50 percent of respondents answered that machine learning for optimisation of manufacturing processes will be the technology that will be used routinely in the pharmaceutical industry by 2026. The post AI to revolutionise drug development by 2026 appeared first on European Pharmaceutical Review.

FDA 105

FDA Pharmaceutical Companies Pharmaceutical Companies 105

STAT

DECEMBER 30, 2024

Although bipartisan legislation to provide Medicare coverage for obesity treatments has circulated in Congress for more than a decade, the Congressional Budget Office (CBO) ventured to  estimate  the budgetary effects of such a policy for older Americans starting in 2026 for the very first time in a report published in October. 

134

134

PharmaVoice

MARCH 11, 2025

Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.

165

165

STAT

OCTOBER 29, 2024

billion in estimated out-of-pocket savings for people with Medicare prescription drug coverage when the negotiated prices are set to go into effect in 2026.

109

109

Fierce Pharma

MARCH 30, 2023

Pfizer, BMS' Eliquis tops list of drugs destined for Medicare price negotiations in 2026: Moody's kdunleavy Thu, 03/30/2023 - 07:28

79

79

Pharmacy Times

AUGUST 15, 2024

The new prices are expected to go into effect for patients with Medicare Part D on January 1, 2026.

149

149

PharmaVoice

AUGUST 16, 2024

The final negotiations slash drug prices between 38% and 79% for Medicare’s 2026 calendar year.

147

147

Fierce Healthcare

MARCH 15, 2023

CMS gives an early look at how it plans to negotiate Part D drug prices in 2026 dmuoio Wed, 03/15/2023 - 17:35

74

74

Fierce Healthcare

OCTOBER 4, 2024

A proposed rule from the Centers for Medicare & Medicaid Services (CMS) released Oct. | CMS is looking to shake up the risk adjustment model and wants the ability to suspend shady brokers from the insurance marketplace, the agency wrote among other updates in a new proposed rule.

Insurance 105

Insurance 105

STAT

JANUARY 29, 2025

Curie.Bio’s new fund will help the organization double its investing over the next two years: The aim is to invest in between 15 and 20 biotechs this year and up to 25 companies in 2026, the founders told STAT exclusively. Continue to STAT+ to read the full story…

91

91

PharmaVoice

NOVEMBER 5, 2024

Rallybio is headed into a mid-stage trial with enough cash through 2026, but the cyclical market has made the journey difficult.

130

130

Pharmaceutical Technology

NOVEMBER 19, 2024

Regenxbio’s plans toward a BLA filing in 2026 after positive data from the Phase I/II AFINITY DUCHENNE trial.

52

52

Pharmacy Times

AUGUST 30, 2023

Any new prices established after negotiations will be effective on January 1, 2026.

132

132

Mission-Driven Marketing Blog

NOVEMBER 1, 2023

Communities of Excellence 2026 (COE) announces strategic partnerships with TAPP Network and PMG Consulting, to improve the quality of life for our nation.

52

52

The FDA Law Blog

JANUARY 18, 2023

The memorandum outlines CMS’s priorities and timeline for the Initial Price Applicability Year 2026. The topics focus on issues relevant in the first three years of the Negotiation Program—2026 to 2028. Finally, the memorandum has a handy timeline of the key dates associated with the Initial Price Applicability Year 2026.

Dosage 59

Dosage 59

STAT

SEPTEMBER 6, 2023

29, Medicare released its highly anticipated list of 10 therapies for which it plans to establish a price by 2026.

123

123

pharmaphorum

MAY 3, 2024

AI-powered home healthcare model from Cera could save NHS and UK £1bn in 2026 if adopted nationwide, says new study

108

108

Outsourcing Pharma

SEPTEMBER 17, 2024

One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal infections in 2026.

FDA 110

FDA 110

Fierce Pharma

OCTOBER 30, 2024

Ever since the FDA rejected zuranolone in major depressive disorder last year, brai | In the wake of a recent round of layoffs, the company this week revealed that it’s discontinuing a commercial medicine and giving up hopes for a pair of pipeline prospects.

FDA 85

FDA 85

Fierce Pharma

SEPTEMBER 7, 2023

Now that the Centers for Medicare & Medicaid Services (CMS) has revealed its li | Now that the CMS has revealed its list of the first 10 drugs subject to Medicare price negotiations under the Inflation Reduction Act, it’s time to consider the financial implications for affected companies.

82

82

STAT

AUGUST 13, 2024

In a press release, the company said that the cuts would help it extend its cash reserves from the second half of 2026 into 2028. The Bay Area biotech brought in $32 million during the quarter but also reported a net loss of $1.6 Continue to STAT+ to read the full story…

138

138

STAT

APRIL 16, 2024

It would carve grocers, restaurants, and food warehouses out of a major portion of the FDA’s rules, which are meant to help regulators quickly track down the cause of a foodborne outbreak, and it would delay enforcement of the entire food safety program, slated to begin in 2026, by several years.

FDA 135

FDA 135

Pharmaceutical Commerce

AUGUST 16, 2024

By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.

98

98

Pharmaceutical Technology

FEBRUARY 6, 2025

CagriSema, considered a successor to Wegovy, is Novo Nordisks most likely route of gaining GLP-1RA market share back from Eli Lilly.

64

64

Outsourcing Pharma

OCTOBER 3, 2024

The proceeds of the financing will support the development of LoQus23âs lead candidate, a small molecule inhibitor that is expected to enter the clinic in 2026.

94

94

Fierce Healthcare

MAY 7, 2024

New legislation extends the pandemic provisions for two more years, through 2026. | Pandemic-era Medicare telehealth flexibilities which removed restrictions on how a Medicare beneficiary could access telehealth are set to expire at the end of 2024. The offsets for the bill include pharmacy benefit manager reforms.

105

105

Drug Store News

FEBRUARY 24, 2023

Target plans to spend $100 million to expand its package-sorting network to more than 15 facilities by the end of 2026.

Packaging 98

Packaging 98

Fierce Pharma

SEPTEMBER 28, 2023

Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business. Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business.

81

81

STAT

OCTOBER 9, 2024

The Congressional Budget Office estimates that 29 million beneficiaries would qualify for weight loss drugs in 2026.    Drugs for those conditions already exist, and they’re often generic. But a lot of people are switching to GLP-1s.   Continue to STAT+ to read the full story…

123

123

Drug Store News

JULY 31, 2023

Sandoz will invest roughly $90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia, by 2026.

97

97

STAT

JUNE 18, 2024

Freespira CEO Joe Perekupka told STAT the company believes it will break even by the end of 2025 and will become cash flow positive in 2026. Perekupka said Freespira hopes to enroll 2,500 people in its treatment this year — twice last year’s sales — and to double its patients again in 2025 and 2026.

Insurance 100

Insurance 100

STAT

SEPTEMBER 20, 2024

The new guidance will affect nearly 6,000 universities and other institutions with projects funded by HHS, which have until 2026 to comply.

124

124

Fierce Healthcare

JULY 14, 2023

It is expected that a new episode-based payment model would be implemented no earlier than 2026, CMMI said. The Center for Medicare and Medicaid Innovation (CMMI) has released a request for information to design a future episode-based payment model. |

98

98

STAT

FEBRUARY 1, 2024

  The negotiated prices won’t take effect until 2026.  The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends.    Continue to STAT+ to read the full story…

Pharmaceutical Companies 119

Pharmaceutical Companies Pharmaceutical Companies 119

Pharmacy Times

MARCH 7, 2025

The treatment is currently undergoing evaluation in an investigational preclinical program and is projected to be in human trials in 2026.

FDA 73

FDA 73

STAT

SEPTEMBER 4, 2024

The sites are expected to employ another 90 people and open by 2026.  The pharmaceutical giant will spend more than $200 million to construct the new facility in Carlsbad, Calif., and expand its site in Indianapolis, representatives told STAT exclusively.

109

109

Fierce Pharma

SEPTEMBER 5, 2023

The case was filed Friday in New Jersey federal court, three days after the CMS revealed that Novartis’ heart failure treatment Entresto was among 10 drugs subject to price negotiations in 2026.

106

106